Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years

Based on its mechanism as an HbS polymerization inhibitor, voxelotor improves Hb levels and markers of hemolysis and has the potential to mitigate SCD-related complications; these results support its use in patients aged ≥4 years.